T he need to further reduce morbidity and mortality in patients with heart failure is undisputed. Certain drug and device therapies have already been remarkably successful in attaining these goals, but more are needed (1,2). Vagus nerve stimulation is a rational, novel approach to treating heart failure that has experimental support (3-6).
Of course, the efficacy of any new treatment must be demonstrated in an appropriately designed clinical trial. Designing and conducting trials using devices is more challenging than trials using drugs, and the investigators, Gold et al. (7) , who led the INOVATE-HF (Increase Of Vagus TonE in Heart Failure) trial published in this issue of the Journal are to be congratulated.
Unfortunately, INOVATE-HF did not show any benefit from vagus nerve stimulation in patients with heart failure and reduced ejection fraction, well treated with evidence-based drug and device therapy.
Whenever a trial fails to demonstrate benefit, it is inevitable that there is an intellectual autopsy. For example, was the trial design optimal? Was the trial conduct satisfactory? Did the patients receive the treatment, and was the dosage correct? Was there an unexpected "off-target" harmful effect of the treatment studied, offsetting any benefit? Or was it simply that the scientific hypothesis was wrong, after all?
Key to the success of any trial is accrual of a suf- 
HOW DOES INOVATE-HF MATCH UP TO THESE STANDARDS?
The patients enrolled in INOVATE-HF were appropriate, well-characterized, and well-treated and, consequently, at relatively low risk. The primary efficacy outcome varied somewhat from that most commonly used in recent heart failure trials (i.e., the composite of cardiovascular death or heart failure hospitalization) (8) (9) (10) (11) . One difference was use of allcause mortality, which has the advantage of objectivity but the disadvantage of including events (i.e., McMurray has reported that he has no relationships relevant to the contents of this paper to disclose. HF and other studies (7, 14) .
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The investigators do not report the expected event rate or anticipated treatment effect size. However, the relatively small sample size (n ¼ 707) and modest target number of primary efficacy endpoints (n ¼ 376 events) suggest a sizeable treatment effect was expected, perhaps one that was unrealistically large.
As it turned out, INOVATE-HF was terminated early 3. Hauptman PJ, Schwartz PJ, Gold MR, et al.
